EBX-102-02, A Full-Spectrum Microbiome Drug, Shows Promise for IBS-C in Phase 2a Trial
HCP Live - 06 May 2025EBX-102-02, A Full-Spectrum Microbiome Drug, Shows Promise for IBS-C in Phase 2a Trial ...
phase 2a
EBX-102-02, A Full-Spectrum Microbiome Drug, Shows Promise for IBS-C in Phase 2a Trial ...
Zetagen Therapeutics Announces Successful Completion of Enrollment in Phase 2a Clinical Study of ZetaMet™ (Zeta-BC-003) Metastatic Breast Cancer
Business Wire - 06 May 2025Zetagen Therapeutics Announces Successful Completion of Enrollment in Phase 2a Clinical Study of ZetaMet™ (Zeta-BC-003) Metastatic Breast Cancer ...
Topas Therapeutics’ TPM502 Achieves Gluten-specific
GlobeNewswire - 06 May 2025Topas Therapeutics’ TPM502 Achieves Gluten-specific ...
Perfuse Therapeutics Announces Positive Results from the Completed Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma
PR Newswire - 06 May 2025Perfuse Therapeutics Announces Positive Results from the Completed Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma ...
ASX Health Quarterly Wrap: Island completes Phase 2a/b dengue trial
Stockhead - 01 May 2025ASX Health Quarterly Wrap: Island completes Phase 2a/b dengue trial ...
Marea Therapeutics Presents Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93rd EAS Congress
The Joplin Globe - 07 May 2025Marea Therapeutics Presents Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93rd EAS Congress ...
Island’s phase 2a/b dengue results in May
The Australian - 23 Apr 2025Island’s phase 2a/b dengue results in May ...
A Phase 2a Double-Blind, Placebo-Controlled, Randomized Clinical Trial Evaluating the Efficacy and Safety of NuGel, a Novel Topical GPCR19-Mediated Inflammasome Inhibitor, in Patients with Mild to Moderate Atopic Dermatitis: A Proof-of-Concept Study wi
Frontiers - 21 Apr 2025A Phase 2a Double-Blind, Placebo-Controlled, Randomized Clinical Trial Evaluating the Efficacy and Safety of NuGel, a Novel Topical GPCR19-Mediated Inflammasome Inhibitor, in Patients with Mild to Moderate Atopic Dermatitis: A Proof-of-Concept Study wi ...
Inmagene Reports Topline Results from Phase 2a Study of
GlobeNewswire - 24 Apr 2025Inmagene Reports Topline Results from Phase 2a Study of ...
Rivus Pharmaceuticals Announces Publication of Phase 2a HuMAIN Trial of HU6 in Patients with Obesity-Related Heart Failure in JAMA Cardiology
PR Newswire - 12 Mar 2025Rivus Pharmaceuticals Announces Publication of Phase 2a HuMAIN Trial of HU6 in Patients with Obesity-Related Heart Failure in JAMA Cardiology ...
Ventus Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating VENT-02, an Oral, Brain-Penetrant NLRP3 Inhibitor, in Parkinson’s Disease
Business Wire - 10 Mar 2025Ventus Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating VENT-02, an Oral, Brain-Penetrant NLRP3 Inhibitor, in Parkinson’s Disease ...
Lipella Reports Positive Phase 2a Results from Second
GlobeNewswire - 22 Apr 2025Lipella Reports Positive Phase 2a Results from Second ...
Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial
PR Newswire - 15 Apr 2025Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial ...
Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis
Business Wire - 27 Mar 2025Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis ...
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus
GlobeNewswire - 11 Feb 2025Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus ...
Artax Biopharma to present Phase 2a data on Nck modulator
GlobeNewswire - 23 Apr 2025Artax Biopharma to present Phase 2a data on Nck modulator ...
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus
GlobeNewswire - 08 Apr 2025Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus ...
AmMax Bio Announces First Patient Dosed in Phase 2a Study
GlobeNewswire - 27 Jan 2025AmMax Bio Announces First Patient Dosed in Phase 2a Study ...
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
GlobeNewswire - 20 Dec 2024InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 ...